These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 3002388

  • 1. Inhibition of human platelet cyclic AMP phosphodiesterase and of platelet aggregation by a hemisynthetic flavonoid, amentoflavone hexaacetate.
    Beretz A, Briançon-Scheid F, Stierlé A, Corre G, Anton R, Cazenave JP.
    Biochem Pharmacol; 1986 Jan 15; 35(2):257-62. PubMed ID: 3002388
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of cyclic AMP phosphodiesterase activity of human blood platelet membrane by ADP.
    Kahn NN, Sinha AK.
    Biochim Biophys Acta; 1989 Aug 21; 984(1):113-8. PubMed ID: 2548620
    [Abstract] [Full Text] [Related]

  • 3. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
    Hidaka H, Hayashi H, Kohri H, Kimura Y, Hosokawa T, Igawa T, Saitoh Y.
    J Pharmacol Exp Ther; 1979 Oct 21; 211(1):26-30. PubMed ID: 226672
    [No Abstract] [Full Text] [Related]

  • 4. Imidazoquinoline derivatives: potent inhibitors of platelet cAMP phosphodiesterase which elevate cAMP levels and activate protein kinase in platelets.
    Seiler S, Gillespie E, Arnold AJ, Brassard CL, Meanwell NA, Fleming JS.
    Thromb Res; 1991 Apr 21; 62(1-2):31-42. PubMed ID: 1649498
    [Abstract] [Full Text] [Related]

  • 5. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.
    Ruppert D, Weithmann KU.
    Life Sci; 1982 Nov 08; 31(19):2037-43. PubMed ID: 6294426
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of rabbit platelet phosphodiesterase activity and aggregation by calcium channel blockers.
    Moore JB, Fuller BL, Falotico R, Tolman EL.
    Thromb Res; 1985 Nov 01; 40(3):401-11. PubMed ID: 2417362
    [Abstract] [Full Text] [Related]

  • 7. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
    Lam SC, Guccione MA, Packham MA, Mustard JF.
    Thromb Haemost; 1982 Apr 30; 47(2):90-5. PubMed ID: 6285543
    [Abstract] [Full Text] [Related]

  • 8. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
    Liu FC, Liao CH, Chang YW, Liou JT, Day YJ.
    Biochem Pharmacol; 2009 Apr 15; 77(8):1364-73. PubMed ID: 19426675
    [Abstract] [Full Text] [Related]

  • 9. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
    Muggli R, Tschopp TB, Mittelholzer E, Baumgartner HR.
    J Pharmacol Exp Ther; 1985 Oct 15; 235(1):212-9. PubMed ID: 2995647
    [Abstract] [Full Text] [Related]

  • 10. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets.
    Simpson AW, Reeves ML, Rink TJ.
    Biochem Pharmacol; 1988 Jun 15; 37(12):2315-20. PubMed ID: 2455518
    [Abstract] [Full Text] [Related]

  • 11. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233.
    Dawicki DD, Agarwal KC, Parks RE.
    Thromb Res; 1986 Jul 15; 43(2):161-75. PubMed ID: 3016942
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of human platelet aggregation by dihydropyrano- and dihydrofuranocoumarins, a new class of cAMP-phosphodiesterase inhibitors.
    Thastrup O, Knudsen JB, Lemmich J, Winther K.
    Biochem Pharmacol; 1985 Jun 15; 34(12):2137-40. PubMed ID: 2988567
    [Abstract] [Full Text] [Related]

  • 13. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin.
    Beretz A, Stierle A, Anton R, Cazenave JP.
    Biochem Pharmacol; 1982 Nov 15; 31(22):3597-600. PubMed ID: 6295405
    [Abstract] [Full Text] [Related]

  • 14. Antithrombotic nipecotamide increases cyclic AMP levels and inhibits protein phosphorylation in human platelets.
    Handa RK, Dillingham EO, Gollamudi R.
    Life Sci; 1995 Nov 15; 57(10):983-8. PubMed ID: 7643723
    [Abstract] [Full Text] [Related]

  • 15. Potentiation of antiaggregating activity of adenosine by a phosphodiesterase inhibitor, EG626 (oxagrelate), in human platelets in vitro.
    Azuma H, Takashima Y, Ishikawa M, Yamakado T.
    Jpn J Pharmacol; 1984 Feb 15; 34(2):159-70. PubMed ID: 6205194
    [Abstract] [Full Text] [Related]

  • 16. Effects of adenosine on levels of adenosine cyclic 3',5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation.
    Haslam RJ, Rosson GM.
    Mol Pharmacol; 1975 Sep 15; 11(5):528-44. PubMed ID: 170501
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography.
    Umekawa H, Tanaka T, Kimura Y, Hidaka H.
    Biochem Pharmacol; 1984 Nov 01; 33(21):3339-44. PubMed ID: 6093810
    [Abstract] [Full Text] [Related]

  • 19. Human platelet aggregation and cAMP system--cAMP level, adenyl cyclase, phosphodiesterase.
    Wang TY, Hussey CV, Sasse EA, Fobian JE.
    Ann Clin Lab Sci; 1978 Nov 01; 8(5):403-12. PubMed ID: 213009
    [Abstract] [Full Text] [Related]

  • 20. Role of plasma adenosine in the antiplatelet action of HL 725, a potent inhibitor of cAMP phosphodiesterase: species differences.
    Agarwal KC, Buckley RS, Parks RE.
    Thromb Res; 1987 Jul 15; 47(2):191-200. PubMed ID: 2821650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.